Follow the Pundits
Tag: Hedge Fund Moves
Biotech Investor Extraordinaire Baker Bros Adds to Its Massive Stake in Kymera. Should You Buy In?
Baker Bros — the Warren Buffetts of biotech — just super-sized their Kymera (KYMR) position. With Fast Track designation, jaw-dropping STAT6 trial results, and a pioneering protein-degradation platform, is KYMR becoming the next biotech legend?
Michael Burry of Scion Asset Management Sees Regeneron Pharmaceuticals Regenerate. Should You Buy In Too?
Michael Burry of The Big Short fame just made Regeneron his second-largest bet. Institutions agree. Is this biotech giant ready to regenerate portfolios?